Sponsors
TITLE SPONSOR
Life Technologies Corporation is a global biotechnology tools company dedicated to improving the human condition. Life Technologies’ systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies’ customers do their work across the biological spectrum, working to advance personalized medicine, stem cell research, regenerative science, molecular diagnostics, agricultural and environmental research and 21st century forensics. As a leading provider of novel stem cell research tools, Life Technologies provides more than 1,500 products used by stem cell scientists in basic research, screening and drug discovery and therapeutic applications. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems, Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products.
LEAD SPONSORS
Advanced BioHealing (ABH), a Shire company, specializes in the development and commercialization of regenerative medicine therapies. ABH currently manufactures and markets Dermagraft®, a bio-engineered skin substitute approved by the FDA for the treatment of diabetic foot ulcers. Dermagraft contains fibroblasts that secrete human dermal collagen, matrix proteins and growth factors.
Progenitor Cell Therapy (PCT) is an internationally recognized commercial client-oriented service company, with a long-term commitment to the development, manufacturing and commercialization of our client’s cell therapies. PCT offers its clients cost-effective, on-demand service solutions, including consulting and regulatory support, GLP/GTP/cGMP-compliant product development and manufacturing services, as well as storage, distribution and logistics support. PCT’s goal is to establish a tailor-made service platform providing each client with four core benefits: unmatched cell therapy-specific focus and expertise, maximal financial value, operational leverage and control over product development and IP and overall risk mitigation throughout the development and commercialization process. With state-of-the-art manufacturing facilities located in Allendale, New Jersey, and Mountain View, California, PCT maintains a California Drug Manufacturing License, is registered with the FDA as a HCT/P facility, and maintains cGMP compliant Quality Systems.
ROTH Capital Partners, LLC is a relationship-driven investment bank focused on identifying growth opportunities for corporate and institutional clients. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading and market-making services. ROTH, headquartered in Newport Beach, California, is privately held and owned by its employees, and maintains offices throughout the United States, Hong Kong and a Shanghai Representative Office.
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The company’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. The company is also developing sequence-specific ZFP Nucleases (ZFN) for targeted gene modification. Sangamo has a Phase 1/2 and two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and a Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Additional therapeutic programs are focused on Parkinson’s disease, hemophilia and other monogenic diseases. Sangamo has secured a dominant intellectual property in the ZFP field and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences (plant agriculture) and Sigma-Aldrich Corporation (research applications and therapeutic protein production).
MAJOR SPONSORS
Hensel Phelps Construction Co. is one of the largest general contractors and construction managers in the United States, ranked consistently among ENR’s (Engineering News-Record) top 20 Contractors. Founded in 1937 by a small, local builder in Greeley, Colorado, Hensel Phelps Construction Co. has grown into a multi-billion dollar, employee-owned, national contractor with an eclectic and unparalleled portfolio of successfully completed projects, including the new Sanford Consortium for Regenerative Medicine building.
Caring for the world, one person at a time, has inspired and united the people of Johnson & Johnson for 125 years. We embrace research and science — bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
EM.D. Millipore is a world-class Life Science partner that offers cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a leading Stem Cell tools provider and strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research through development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals.
Having pioneered the field, Massachusetts based Organogenesis, Inc. is a world leading regenerative medicine company focused in the areas of bio-active wound healing and bio-surgery. The company’s mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. The company’s lead product, Apligraf®, a bilayered living cellular construct to treat non-healing wounds, has been used to treat hundreds of thousands of patients.
Pfizer applies science and global resources to improve health and well-being at every stage of life. The company strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Pfizer’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with the responsibility as the world’s leading biopharmaceutical company, Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on them.
The Custom Biotech arm of Roche Diagnostics develops and markets solutions for the biomedical and research industries and provides a wide range of products used for in-process quality control testing as well as pharma biotech enzymes for dissociating cells from primary tissues, downstream proteases and biocatalysts. Roche is setting a new standard for tissue-dissociation enzymes with the introduction of our GMP-quality “mammalian tissue-free” Liberase® Enzyme Blends. Roche’s portfolio contains highly purified collagenase with thermolysin or neutral protease enzyme that offers stem cell researchers the tools for optimizing their stem cell isolation protocols to maximize cell yields, viability, functionality and safety.
CONTRIBUTING SPONSOR
Agilent Technologies is a leading provider of instrumentation, supplies, software and services to the life sciences. Agilent’s 25,000+ customers range from global pharmaceutical corporations to biotech companies, government labs and academic researchers. Agilent tools help scientists to understand complex biological processes, unlock the causes of disease and speed the discovery of new drugs. Agilent provides products throughout the entire pharmaceutical value chain from basic research to drug manufacturing quality control.
Athersys is a biopharmaceutical company that is committed to developing therapeutic products that have best-in-class potential. The company’s lead product development programs utilize MultiStem®, a patented and proprietary stem cell product that could be beneficial in the treatment for multiple disease indications in the cardiovascular, neurological and inflammatory and immune disease areas, as well as certain other conditions. MultiStem® is currently being evaluated in several clinical stage programs, as well as a range of preclinical programs. Athersys is also developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions and certain neurological disorders.
From isolation through production, BD Biosciences delivers high-quality products and services, meeting your needs at key steps in the cell-based workflow. As research moves toward clinical trials and ultimately new cell therapies, you can rely on BD’s proven experience in delivering quality GMP products and services. Look forward to the next generation of tools and systems to help you transform disease management in the next decade.
www.bdbiosciences.com/stemcell
Crescent Chemical Company is the US distributor for this GMP Collagenase which is a mild and effective enzyme and produces consistently high yields of viable cells. Serva Collagenase NB6 GMP is currently the only cGMP compliant Collagenase on the market which has been optimized for isolation and passaging of stem cells designated for transplantation into humans. Collagenase NB6 GMP is produced by the world’s largest pharmaceutical manufacturer of Collagenase. It is sterile and ready for immediate use, and meets stringent safety standards such as TSE safety testing and very low endotoxin levels. In addition, data for virus validation and stability studies according to ICH guidelines are available.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. EBD Group’s conferences are run with the support of leading corporations and international trade associations, and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO);
- BioPharm America™, the fastest growing partnering event in North America;
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry;
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO;
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC;
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world. Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in the USA and Europe.
International Stem Cell Corporation (ISCO) develops a powerful new stem cell technology called parthenogenesis that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. Parthenogenesis utilizes unfertilized human eggs to create parthenogenetic stem cells (hpSC) that can be immune-matched to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover a large part of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world.
Molecular Diagnostic Services, Inc. (MDS) is an independent contract service organization since 1992, providing comprehensive cellular and molecular biology, microbiology, sterility assurance, biocompatibility and toxicology services to pharmaceutical, biotechnology, medical device and research institutions. MDS is prepared to serve as a non-GLP/GMP or strictly as a GLP/GMP contract resource for developed or pre-defined protocols for national and international clients. On the cutting edge of technology for decades, MDS provides expert services in the fields of cellular and molecular biology, assay development, assay validation, cell identity, paternity, mutagenesis, in vitro toxicity, in vivo toxicity as well as quality control services. MDS’ fundamental mission is helping clients to maximize the return on their R&D investments. MDS also produces customized and specialty molecular biology reagents. MDS provides prompt, comprehensive service to companies ranging from large international to small start-up firms. For some companies, MDS has become their in-house laboratory. Other clients use the company to supplement their own capabilities-for special projects or to meet peak demand.
Organovo is a three-dimensional biology company with a proprietary technology known as bioprinting that enables creation of functional 3D tissue that highly conserves native structure. The company utilizes primary human cells, human cell lines and stem cell sources to print various structures that mature into functional tissue in a number of applications. The company has developed commercial disease models that have been developed for pharma partners. These models can be superior to animal models and simple cell based assays. Fibrosis, liver toxicology, diabetes and oncology are just a sampling of areas where 3D is necessary to replicate true tissue biology.
Spencer Trask is a private equity firm committed to discovering ideas to shape the 21st Century. Through a collaborative network of business leaders, leading edge scientists and engineers, innovators and co-investors – the Spencer Trask Network – the firm provides visionary entrepreneurs with both the intellectual and financial capital to transform bright ideas into world-changing companies. Spencer Trask’s portfolio encompasses emerging communications, information technologies and healthcare including bio-tech medical devices. Spencer Trask’s unique business building approach focuses on one purpose: building great companies.
Stemedica is a global biotechnology company specializing in the development, manufacture and distribution of allogeneic adult stem cell products. Stemedica’s core mission is to develop, manufacture and distribute adult stem cells that have the potential to save, restore and improve lives.
Licensed by the Food and Drug Branch of the State of California, Stemedica manufactures clinical grade stem cells, stem cell factors and related biologics under cGMP standards. Our products are specially formulated to provide Stemedica with the ability to create multiple formulations designed to address specific medical conditions or disease states and are used by scientists and clinicians worldwide for research and clinical trials. Stemedica also has an IND from the FDA for its current Phase I/II clinical trial for ischemic stroke being conducted at UCSD.
With an experienced team of international and domestic scientists and medical professionals, Stemedica continues to advance and refine its adult stem cell technology.
Organized By
